ZANTAC 150 Drug Patent Profile

When do Zantac 150 patents expire, and when can generic versions of Zantac 150 launch?

Zantac 150 is a drug marketed by Glaxosmithkline, Glaxo Grp Ltd, and Chattem Sanofi. and is included in four NDAs.

The generic ingredient in ZANTAC 150 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zantac 150

A generic version of ZANTAC 150 was approved as ranitidine hydrochloride by SANDOZ on August 29^th, 1997.

Summary for ZANTAC 150

US Patents:	0
Applicants:	3
NDAs:	4
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	22
Patent Applications:	4
What excipients (inactive ingredients) are in ZANTAC 150?	ZANTAC 150 excipients list
DailyMed Link:	ZANTAC 150 at DailyMed

Recent Clinical Trials for ZANTAC 150

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Spaulding Clinical Research LLC	Phase 1
Food and Drug Administration (FDA)	Phase 1
Nova Scotia Health Authority	Phase 4

See all ZANTAC 150 clinical trials

US Patents and Regulatory Information for ZANTAC 150

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	ZANTAC 150	ranitidine hydrochloride	CAPSULE;ORAL	020095-001	Mar 8, 1994		DISCN	Yes	No
Chattem Sanofi	ZANTAC 150	ranitidine hydrochloride	TABLET;ORAL	021698-001	Aug 31, 2004		DISCN	Yes	No
Glaxo Grp Ltd	ZANTAC 150	ranitidine hydrochloride	GRANULE, EFFERVESCENT;ORAL	020251-002	Mar 31, 1994		DISCN	No	No
Glaxo Grp Ltd	ZANTAC 150	ranitidine hydrochloride	TABLET, EFFERVESCENT;ORAL	020251-001	Mar 31, 1994		DISCN	No	No
Glaxo Grp Ltd	ZANTAC 150	ranitidine hydrochloride	TABLET;ORAL	018703-001	Jun 9, 1983		DISCN	Yes	No
Chattem Sanofi	ZANTAC 150	ranitidine hydrochloride	TABLET;ORAL	021698-002	Mar 13, 2007		DISCN	Yes	No

Expired US Patents for ZANTAC 150

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chattem Sanofi	ZANTAC 150	ranitidine hydrochloride	TABLET;ORAL	021698-002	Mar 13, 2007	5,098,715
Glaxosmithkline	ZANTAC 150	ranitidine hydrochloride	CAPSULE;ORAL	020095-001	Mar 8, 1994	4,128,658
Glaxo Grp Ltd	ZANTAC 150	ranitidine hydrochloride	TABLET, EFFERVESCENT;ORAL	020251-001	Mar 31, 1994	4,128,658
Glaxo Grp Ltd	ZANTAC 150	ranitidine hydrochloride	TABLET;ORAL	018703-001	Jun 9, 1983	4,128,658
Glaxo Grp Ltd	ZANTAC 150	ranitidine hydrochloride	GRANULE, EFFERVESCENT;ORAL	020251-002	Mar 31, 1994	4,128,658

International Patents for ZANTAC 150

See the table below for patents covering ZANTAC 150 around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	375931
Austria	381937
Austria	A322880
Austria	A574077
Australia	2751977
Australia	515628
Belgium	857388

Market Dynamics and Financial Trajectory for ZANTAC 150

Last updated: January 29, 2026

---

Summary

ZANTAC 150 (ranitidine), once a leading medication for gastric acid reduction, experienced a substantial market decline following safety concerns related to impurities and subsequent recalls in 2019. This report analyzes the evolution of ZANTAC 150’s market position, regulatory challenges, financial impact, and future prospects. It evaluates the drug’s market share, competitors, legal liabilities, and potential pathways for recovery or replacement strategies within the pharmaceutical landscape.

---

What Is the Historical Market Position of ZANTAC 150?

Product Overview

• Active Ingredient: Ranitidine hydrochloride
• Dosage: 150 mg
• Indications: GERD, gastric ulcers, Zollinger-Ellison syndrome
• Launch Date: 1981
• Initial Market Leadership: Dominated the H2-receptor antagonist segment with approximately 60% market share (early 2000s).

Market Milestones

Year	Key Events	Market Share	Revenue (USD)	Notes
1980s-1990s	Launch and rapid adoption	~60%	Billions USD	Top-seller in OTC and prescription segments.
2000s-2010	Competitive pressure from PPIs (e.g., omeprazole)	Declining	Decreasing	Market share decreased to ~40% by 2010.
2013-2018	Increased use in OTC segment	Stable/declining	USD 1-2 billion	Continued decline as PPIs gained preference.

Sales Breakdown (Pre-2019)

Segment	Approximate Market Share	Revenue Estimate (USD)	Notes
Prescription	60%	$1.5 billion	Dominated by legacy prescriptions
OTC	40%	$1 billion	Popular for self-medication

---

What Led to the Decline of ZANTAC 150 in 2019?

Safety Concerns & Regulatory Actions

• NDMA Contamination: N-Nitrosodimethylamine (NDMA), a probable human carcinogen, was detected in ranitidine products. The presence increased over time and under stress conditions.
• Recall Initiatives: Major regulatory agencies, including the FDA and EMA, issued voluntary recalls starting in September 2019.

Date	Agency	Action	Impact
Sept 2019	FDA	Recall of all ranitidine products	Product removal from market
Ongoing	EMA & others	Continued investigation & bans	Market exit globally

Legal and Litigation Impacts

• Filed lawsuits alleged possible cancer risks linked to NDMA exposure.
• Multibillion-dollar lawsuits accumulated, further eroding market confidence.
• Manufacturer liability concerns exacerbated the product discontinuation.

Supply Chain Disruptions

• Discontinued manufacturing led to shortages, affecting pharmacies and hospitals.
• Replacement therapies gained market share swiftly.

---

What Are the Current Market Dynamics Post-Recall?

Factor	Impact/Trend	Source/Observation
Market Exit	Sharp decline in sales and market presence	Sales data from IQVIA (2020-2022)
Competitors	Growth of PPIs (e.g., omeprazole, esomeprazole)	Market reports, Novartis, AstraZeneca
Legal Uncertainty	Ongoing lawsuits affecting manufacturer confidence	Legal filings overview
Regulatory Environment	Stringent testing and impurity limits	US FDA, EMA guidelines
Public Perception	Increased safety concerns, reduced trust	Consumer surveys, market sentiment analysis

Market Share Shift (2019-2023)

Segment	Pre-2019 Sale Share	Post-2019	Notes
H2-receptor antagonists	~20-30%	e.g., <5%	Major erosion, replaced by PPIs
PPIs	50-60%	+20% in market share	Benefited from ranitidine decline
Other therapies	N/A	Stable/Increasing	Antacids, surgery, alternative meds

---

What Are the Regulatory and Strategic Implications?

Regulatory Landscape

• Stringency: Post-2019, regulatory agencies have enforced tighter impurity controls in drug manufacturing.
• Product Reapprovals: Ranitidine regained approval only where impurities are minimized; however, widespread re-approval remains unlikely.

Strategic Responses by Stakeholders

Stakeholder	Actions	Outlook
Manufacturers (e.g., Sanofi, Mylan)	Recall, litigation, formulation reformulation	Limited potential for re-entry without reformulation
Competitors (PPIs)	Accelerated R&D and market capture	Gaining long-term market benefits
Regulators	Enhanced surveillance, impurity limits	Higher compliance costs, barriers for legacy drugs

---

What Does the Future Hold for ZANTAC 150 and Similar Drugs?

Scenario	Likelihood	Description	Key Factors
Complete Market Exit	High	Given safety issues, regulatory bans, and legal liabilities	NDMA risk, consumer safety concerns
Reformulation & Re-approval	Moderate	Reformulating to eliminate NDMA and reintroducing under strict regulation	Legislative and scientific hurdles
Niche or Legacy Market Preservation	Low	Limited use in specific clinical circumstances or compounded forms	Mainly in legacy systems
Transition to Alternative Therapies	High	Shift towards PPIs, antacids, or surgical interventions	Cost, efficacy, safety profiles

---

Comparison with Competitors

Criteria	ZANTAC (Ranitidine)	PPIs (e.g., Omeprazole, Esomeprazole)	Antacids	Surgery
Market Presence (Pre-2019)	Dominant	Growing	Significant in OTC	Niche, specialized procedures
Safety Concerns (NDMA)	Major recall, banned	Generally considered safe	Safe (short-term)	Invasive, reserved for severe cases
Regulatory Environment	Stringent post-2019	Stable	Stable	Variable depending on type
Cost	Moderate to high	Often reimbursed or OTC	Low	High (surgical costs)

---

Key Market Challenges for Re-Entry

• Regulatory Hurdles: Demonstrating absence of NDMA or similar impurities at permissible levels.
• Legal Risks: Ongoing litigation increases liabilities.
• Consumer Trust: Restoring safety confidence is critical.
• Market Competition: PPIs and other therapies have entrenched positions.

---

Financial Impact Analysis

Impact Area	Estimated Loss (USD)	Explanation
Revenue (Global) Impact	$3–5 billion (2019-2022)	Cumulative decline based on market share erosion and recall costs
Litigation & Settlements	$1–2 billion (projected)	Ongoing legal liabilities
R&D & Reformulation Costs	$50–100 million per effort	Estimated costs for reformulation or new manufacturing process
Stock & Market Capitalization	Significant decline (~30%)	Share price drop and market cap reduction

---

Conclusion

The downfall of ZANTAC 150 exemplifies how safety concerns, regulatory actions, and legal liabilities can devastate a once-dominant pharmaceutical product. Post-2019, the drug’s market has largely evaporated, replaced by PPIs and other therapies. Although reformulation strategies could technically allow re-entry, the cumulative regulatory, legal, and consumer trust barriers make revival unlikely in the near term.

Future market evolution will depend heavily on regulatory reforms, advances in formulation technology, and legal outcomes. The broader legacy warns industry stakeholders to uphold rigorous safety standards, especially concerning trace impurities like NDMA.

---

Key Takeaways

• ZANTAC 150 was a market leader for decades before NDMA-related recalls caused its decline.
• The global market for ranitidine effectively disappeared by 2022, replaced mainly by PPIs.
• Regulatory compliance and safety guarantee are paramount for re-approval prospects.
• Legal liabilities impose significant financial burdens, discouraging re-entry.
• Competitors benefit from the vacuum created, consolidating their market positions.
• Future of ZANTAC 150 is limited; reformulation and legal settlements present some opportunities but with considerable challenges.

---

FAQs

1. Is ZANTAC 150 completely banned worldwide?
While many regulatory agencies, including the FDA and EMA, have banned or withdrawn ranitidine products due to NDMA contamination, some jurisdictions may still permit limited or compounded uses. However, widespread availability is severely restricted.

2. Can ZANTAC 150 be reformulated and safely reintroduced?
Potentially, if manufacturers can eliminate NDMA formation through reformulation techniques, re-approval may be feasible. Nevertheless, extensive testing, regulatory review, and legal clearance are prerequisites.

3. How do PPIs compare to ranitidine in terms of safety?
PPIs like omeprazole have a different safety profile, generally considered safe but with concerns over long-term use, including nutrient deficiencies and increased risk of infections. They have not faced comparable carcinogen issues.

4. What legal liabilities are associated with ZANTAC?
Numerous lawsuits allege cancer risk linked to NDMA exposure, leading to multibillion-dollar settlements and verdicts. These liabilities substantially impact companies' financial positions and strategic options.

5. What is the outlook for stakeholders holding ZANTAC-related patents or formulations?
Patent holders face substantial challenges due to market withdrawal, legal liabilities, and regulatory restrictions. Opportunities may lie in developing reformulated versions or alternative therapies, contingent on regulatory approval.

---

References

[1] U.S. Food and Drug Administration (FDA). "Recall of Ranitidine (Zantac) and other formulations." 2019.

[2] European Medicines Agency (EMA). "Safety Update on Ranitidine." 2019.

[3] IQVIA. "Pharmaceutical Market Data." 2020–2022.

[4] Novartis, AstraZeneca Market Reports. "Proton Pump Inhibitors Market Analysis." 2022.

[5] Legal filings and lawsuit summaries, as sourced from CourtListener and publicly available legal databases, 2020–2023.